trending Market Intelligence /marketintelligence/en/news-insights/trending/HgsPiJSVoQwco0Kd95ZB-Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Vaxart to raise $3M in common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Vaxart to raise $3M in common stock offering

Vaxart Inc. is offering 1.2 million common shares priced at $2.50 apiece in a registered direct offering.

The transaction, which is being participated by certain institutional investors, is expected to generate $3 million in gross proceeds.

The closing of the offering will occur March 20.

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

South San Francisco, Calif.-based Vaxart is focused on developing oral vaccines using its proprietary oral vaccine platform.